{
	"kihkch2xText": "Co<span class=\"_ _1\"></span>gnitiv<span class=\"_ _1\"></span>e symp<span class=\"_ _1\"></span>toms ar<span class=\"_ _1\"></span>e com<span class=\"_ _1\"></span>mon i<span class=\"_ _0\"></span>n MD<span class=\"_ _1\"></span>D<span class=\"_ _1\"></span>, ma<span class=\"_ _1\"></span>y <br><span class=\"ls14 ws1c\">persis<span class=\"_ _4\"></span>t<span class=\"_ _4\"></span> despite<span class=\"_ _4\"></span> tr<span class=\"_ _4\"></span>eatment<span class=\"_ _4\"></span> response or<span class=\"_ _4\"></span> remission, <br><span class=\"ls4 wsf\">inc<span class=\"_ _4\"></span>reasing<span class=\"_ _4\"></span> t<span class=\"_ _4\"></span>he ris<span class=\"_ _4\"></span>k of<span class=\"_ _4\"></span> relapse<span class=\"_ _2\"></span><span class=\"fs3 ls1e ws26 v1\">1-<span class=\"_ _6\"></span>4</span></span></span>",
	"kihkch2yText": "Disease<span class=\"_ _f\"> </span><span class=\"ls13 wsb\">ST<span class=\"_ _1\"></span>AR*D<span class=\"_ _8\"></span><span class=\"ls0 ws0\">T<span class=\"_ _1\"></span>reatment Goals<span class=\"_ _9\"> </span><span class=\"ls13\">Adverse events<span class=\"_ _a\"> </span><span class=\"wsc\">Anhedonia<span class=\"_\"> </span></span>Emotional blunting<span class=\"_ _16\"></span>Cognitive Symptoms in Asia<span class=\"_ _17\"></span><span class=\"ff1 fc1\">Cognitive Symptoms</span></span></span></span>",
	"Brintellix_5a872f4d1": "<div style=\"text-align: center;\"><span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 21px; color: #4d7f86;\">Acute</span></div>",
	"Brintellix_5d2236f1e": "<div style=\"text-align: center;\"><span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 21px; color: #4d7f86;\">Response</span></div>",
	"Brintellix_5821ebcc6": "<div style=\"text-align: center;\"><span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 21px; color: #4d7f86;\">Remission</span></div>",
	"Brintellix_596d0c5f6": "<div style=\"text-align: center;\"><span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 21px; color: #4d7f86;\">Consequences</span></div>",
	"Brintellix_57e4badad": "<div style=\"text-align: center;\"><span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 21px; color: #4d7f86;\">Burden</span></div>",
	"Brintellix_50d763643": "<span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 20px; color: #645e5e;\">During the <b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;;color: #4d7f86;\">acute phase</b>, cognitive symptoms are common in patients with MDD*<sup style=\"line-height:0; font-size:60%;\">5</sup></span>",
	"Brintellix_5a332d3f5": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 11px; color: #645e5e;\">In a 3-year prospective study of 267 initially depressed primary care patients we established per week the  presence/absence of the individual DSM-IV depressive symptoms during subsequent major depressive episodes (MDEs) and episodes of (partial) remission. This was accomplished by means of 12 assessments at 3-monthly intervals with the Composite International Diagnostic Interview (CIDI).</span>",
	"Brintellix_551400cd9": "<div style=\"text-align: center;\"><span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 45px; color: rgb(255, 255, 255);\">94%</span></div>",
	"Brintellix_572e38cd0": "<div style=\"text-align: center;\"><span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 15px; color: rgb(255, 255, 255);\">In one study, cognitive<br>problems dominated and<br><b style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi';\">were present for up to<br>94% of the time</b> during<br>depressive episodes<sup style=\"line-height:0; font-size:60%;\">1</sup><br>(n=267)</span></div>",
	"Brintellix_54771601f": "<span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 20px; color: #645e5e;\">Even when <b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;;color: #4d7f86;\">patients responded to treatment</b>, cognitive symptoms may continue to be highly prevalent and persistent*<sup style=\"line-height:0; font-size:60%;\">2,5</sup></span>",
	"Brintellix_5b99eff70": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 11px; color: #645e5e;\">This report describes the residual symptom domains and individual depressive symptoms in a large representative sample of outpatients with nonpsychotic MDD who responded without remitting after up to 12 weeks of citalopram treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Response was defined as 50% or greater reduction in baseline 16-item Quick Inventory of Depressive Symptomatology–Self-report (QIDS-SR16) by treatment exit, and remission as a final QIDS-SR16 of less than 6.</span>",
	"Brintellix_5b1f5eb6f": "<div style=\"text-align: center;\"><span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 45px; color: rgb(255, 255, 255);\">70%</span></div>",
	"Brintellix_5471f0610": "<div style=\"text-align: center;\"><span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 15px; color: rgb(255, 255, 255);\">Another study showed<br>that <b style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi';\">70% of patients<br>who responded to<br>treatments</b> still had<br>cognitive symptoms<sup style=\"line-height:0; font-size:60%;\">2</sup><br>(n=428)</span></div>",
	"Brintellix_531bcc500": "<span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 20px; color: #645e5e;\">Even during <b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;;color: #4d7f86;\">periods of remission</b>, cognitive symptoms may continue to be highly prevalent and persistent*<sup style=\"line-height:0; font-size:60%;\">2,5</sup></span>",
	"Brintellix_5a57004bb": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 11px; color: #645e5e;\">In a 3-year prospective study of 267 initially depressed primary care patients we established per week the  presence/absence of the individual DSM-IV depressive symptoms during subsequent major depressive episodes (MDEs) and episodes of (partial) remission. This was accomplished by means of 12 assessments at 3-monthly intervals with the Composite International Diagnostic Interview (CIDI).</span>",
	"Brintellix_5c2d1d069": "<div style=\"text-align: center;\"><span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 45px; color: rgb(255, 255, 255);\">44%</span></div>",
	"Brintellix_5d348b428": "<div style=\"text-align: center; line-height: 1.1;\"><span style=\"font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;; font-size: 15px; color: rgb(255, 255, 255);\">Even in patients thought to<br style=\"\">be in remission, cognitive<br>symptoms were shown to<br><b style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi';\">be present in depressed<br style=\"\">patients for an average<br>of 44% of the time</b> during<br>periods of remission<sup style=\"font-size: 60%;\">1</sup><br>(n=267)</span></div>",
	"Brintellix_53c351545": "<span style=\"font-family: &quot;2_VDWFON+AvenirNextLTPro-Demi&quot;; font-size: 20px; color: rgb(100, 94, 94); line-height: 1.2;\"><b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(77, 127, 134);\">Residual cognitive and mood symptoms are predictors of relapse*<sup style=\"font-size: 60%;\">4</sup></b><br>Patients with residual symptoms of depression are 3 times more likely to relapse<sup style=\"font-size: 60%;\">6</sup></span>",
	"Brintellix_52cc6740b": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 11px; color: #645e5e;\">Residual symptoms defined as HAM-D17 total score ≥8. Relapse occurred in 13/17 patients with residual symptoms compared to 10/40 without residual symptoms (p&lt;0.001). Remission was defined as 2 consecutive months, retrospectively rated, below the RDC for primary unipolar major depression. <br>Relapse was defined as a return to satisfy RDC definite major depression for ≥1 month.</span>",
	"Brintellix_58607f2b2": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 15px; color: #4d7f86;\"><div style=\"text-align: center;\">Proportion relapsing</div></span>",
	"Brintellix_58aca2e50": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 22px; color: #4d7f86;\"><div style=\"text-align: center;\">76%</div></span>",
	"Brintellix_5ec467ca7": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 22px; color: #4d7f86;\"><div style=\"text-align: center;\">25%</div></span>",
	"Brintellix_5d791ddca": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; font-size: 15px; color: #4d7f86;\"><div style=\"text-align: center;\">Months between remission and relapse, or end of study</div></span>",
	"Brintellix_51cc49a3d": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 13px; color: #645e5e;\">With residual symptoms</span>",
	"Brintellix_5fef5ac51": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 13px; color: #645e5e;\">Without residual symptoms</span>",
	"Brintellix_57efb5617": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 17px; color: #645e5e;\"><b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;;color: #4d7f86;\">Increases risk of relapse</b><br> \nPatients exhibiting residual cognitive symptoms have been shown to be at increased risk of relapse<sup style=\"line-height:0; font-size:60%;\">1</sup></span>",
	"Brintellix_50bae5107": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 17px; color: #645e5e;\"><b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;;color: #4d7f86;\">Associated with poor patient functioning </b><br> \nCognitive symptoms are associated with impairments in patient functioning and decreased health-related quality of life<sup style=\"line-height:0; font-size:60%;\">1,2</sup></span>",
	"Brintellix_5a3135fb0": "<span style=\"font-family: '3_BNJCUB+AvenirNextLTPro-Regular'; font-size: 17px; color: #645e5e;\"><b style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;;color: #4d7f86;\">Predictor of poor long-term functioning</b><br> \nThe severity of cognitive symptoms has also been reported to be an independent and significant predictor of later functional impairment<sup style=\"line-height:0; font-size:60%;\">3,4</sup></span>",
	"Brintellix_525f79309": "<div style=\"text-align: center;\"><span style=\"font-family: '2_VDWFON+AvenirNextLTPro-Demi'; font-size: 25px; color: rgb(255, 255, 255);\">Cognitive<br>symptoms</span></div>",
	"Brintellix_52750b595": "<span style=\"color: rgb(77, 127, 134); font-family: '15_VDWFON+AvenirNextLTPro-Demi';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_5020787d0": "<font style=\"font-size: 15px; font-family: &quot;2_VDWFON+AvenirNextLTPro-Demi&quot;; color: rgb(100, 94, 94); line-height: 1.5;\"><b style=\"\">1.<br style=\"\">2.<br>3.<br>4.<br><br>5.<br>6.</b></font>",
	"Brintellix_52fc1fb81": "<font style=\"font-size: 15px; font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1.5;\">Conradi HJ et al. Psychol Med 2011;41:1165–1174.<br>Hammar A, Ardal G. Front Hum Neurosci 2009;3:26.<br>McClintock SM et al. J Clin Psychopharmacol 2011;31:180–186.<br>Saragoussi D et al. Poster presented at the American Psychiatric Association 169th Annual Meeting. May 14–18. 2016.<br>Manit et al. Clin Pract Epidemiology Ment Health 2017;13:185-199.<br>Paykel ES et al. Psychol Med 1995;25:1171-80.</font>",
	"Brintellix_5fc503fc8": "<span style=\"color: rgb(77, 127, 134); font-family: '15_VDWFON+AvenirNextLTPro-Demi';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_541c8f752": "<font style=\"font-size: 15px; font-family: &quot;2_VDWFON+AvenirNextLTPro-Demi&quot;; color: rgb(100, 94, 94); line-height: 1.5;\"><b style=\"\">1.<br style=\"\">2.<br>3.<br>4.</b></font>",
	"Brintellix_501b2fa1c": "<font style=\"font-size: 15px; font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1.5;\">Saragoussi D et al. Neuropsychiatr Dis Treat 2017;13:2151–2165.<br>Hammer-Helmich L et al. Neuropsychiatr Dis Treat 2018; 9(14):239–249.<br>Haro JM et al. Neuropsychiatr Dis Treat 2019;15:2313–2323.<br>Chokka P et al. CNS Spectr 2019;Feb 25:1–12.</font>",
	"Brintellix_520cdd774": "",
	"Brintellix_57c08eb05": "",
	"Brintellix_599092d4e": "",
	"Brintellix_575605c9b": "",
	"Brintellix_5ba41c37c": "",
	"Brintellix_5a337cceb": "",
	"Brintellix_5a418b872": "",
	"Brintellix_591e47a17": "",
	"Brintellix_5e095a396": "",
	"Brintellix_540a16893": "",
	"Brintellix_59e25751d": "Text",
	"Brintellix_5deb9d8e4": "Text",
	"Brintellix_5f09a9f65": "Text",
	"Brintellix_52b0e4492": "Text",
	"Brintellix_52cb0668b": "Text",
	"Brintellix_53ef86601": "Text",
	"Brintellix_536fbb0c4": "Text"
}
